Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes
Diabetes Obesity and Metabolism2014Vol. 17(3), pp. 254–260
Citations Over TimeTop 10% of 2014 papers
Masanari Shiramoto, Takashi Eto, S. Irie, A. Fukuzaki, Lenore Teichert, J. Tillner, Yoshinori Takahashi, Masayoshi Koyama, Raphael Dahmen, Tim Heise, R. H. A. Becker
Abstract
Single-dose injections of Gla-300 present more constant and prolonged PK and PD profiles compared with Gla-100, maintaining blood glucose control for up to 36 h in euglycaemic clamp settings in Japanese and European participants with type 1 diabetes.
Related Papers
- → Sensitivity and specificity of dosing alerts for dosing errors among hospitalized pediatric patients(2014)29 cited
- → Efficacy of nivolumab four-weekly dosing schedule based on body weight(2019)10 cited
- → Approaches to maintenance dosing during oral immunotherapy(2022)2 cited
- → The Impact of Role of Pharmacists in Renal Dosage Adjustment Program on Renal Drug Dosing Errors: A Quasi-Experimental Study(2021)1 cited
- → Pharmacokinetics‐Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease(2019)1 cited